ERBB2 and breast carcinoma: Therefore the panel EGFR, MET, HER2, GLUT1, CAIX, and IGF1-R detected 84.2% of the basal/TN ductal breast cancers compared to 45.0% of the luminal-type, and 18.3% of the lobular breast cancer cases (Figure 2A, Tables 3 and 4).